Avoid TMP-SMX in first trimester and near term (folate antagonism and kernicterus risk)
Avoid doxycycline (teratogenic, dental staining)
Severity threshold lower in pregnancy
Physiologic leukocytosis of pregnancy may confound WBC interpretation
Lower threshold for admission and IV therapy
Imaging
Ultrasound preferred for abscess assessment
CT with shielding when clinical benefit outweighs radiation risk
Fetal monitoring
When gestation is viable, continuous fetal heart rate monitoring if febrile
Obstetric consultation for systemic illness
Geriatric
Older adult considerations
Atypical presentation
Afebrile infection common in older adults
Delirium or functional decline as presenting symptom
Lower temperature threshold for concern
Medication safety
Renal dose adjustment for vancomycin and TMP-SMX
Monitor creatinine when on nephrotoxic antibiotics
QT prolongation risk with fluoroquinolones higher in elderly
Comorbidity burden
Diabetes, chronic lymphedema, venous insufficiency common
Higher recurrence rate
Bias toward admission over outpatient management
Recurrence prevention
Prophylactic penicillin V 250 mg PO twice daily for >= 2 episodes per year
Lymphedema management reduces recurrence risk
Pediatrics
Pediatric differences
Etiology
Group A Streptococcus and Staphylococcus aureus most common
Consider MRSA if purulent or failed beta-lactam
Cat-scratch disease common cause of lymphadenitis in children
Weight-based dosing
Cephalexin PO 25 to 50 mg/kg/day divided every 6 to 8 hours
Clindamycin PO 30 to 40 mg/kg/day divided every 6 to 8 hours for MRSA concern
Cefazolin IV 50 mg/kg/day divided every 8 hours for inpatient therapy
Severity markers differ
Age-appropriate heart rate and respiratory rate references
Feeding intolerance as severity marker in infants
Child protection consideration
Unusual or recurrent skin infections without clear mechanism
Safety assessment if neglect concern
Background
Epidemiology
Incidence and burden
Lymphangitis is a complication of cellulitis and wound infection
Complicates approximately 2 to 5% of skin and soft tissue infections
Exact incidence poorly characterized in literature
Group A Streptococcus causes 70 to 90% of acute lymphangitis cases
Staphylococcus aureus second most common
MRSA increasingly prevalent in purulent variants
Risk population concentration
Lymphedema patients have OR 6.8 for recurrent cellulitis and lymphangitis
Diabetic patients have 3-fold higher risk of hospitalization for SSTI
Seasonal and demographic patterns
More common in warm months
Greater skin exposure and outdoor activity
Increased insect bite frequency
No strong sex predilection for acute bacterial lymphangitis
Filariasis-associated chronic lymphangitis more common in endemic tropical areas
Pathophysiology
Mechanisms of infection
Bacterial entry through disrupted skin barrier
Group A Streptococcus invades dermis via any skin breach
Colonization of tinea pedis maceration is major entry route
Spread via lymphatic channels
Bacteria carried through afferent lymphatics proximally
Inflammatory response within lymphatic walls creates visible streak
Regional lymph node involvement
Bacteria filtered at regional nodes causing reactive lymphadenopathy
Nodes may suppurate forming abscesses if infection overwhelms filtering
Systemic spread pathway
Bacteremia risk with proximal spread
Bacteria enter systemic circulation from lymphatics via thoracic duct
Sepsis risk increases as infection approaches axilla or groin
Inflammatory mediator release
Streptococcal exotoxins trigger SIRS response
Severe cases progress to streptococcal toxic shock syndrome
Therapeutic Considerations
Antibiotic strategy principles
Empiric therapy targets Group A Streptococcus as primary pathogen
Beta-lactams provide first-line coverage
MRSA coverage added when purulent, IVDU, or prior MRSA history
Avoid corticosteroids
Can mask underlying malignancy
May worsen infection in immunosuppressed host
No proven benefit in bacterial lymphangitis
IDSA guidelines support 5-day minimum course
Class I recommendation based on RCT evidence
Extension based on clinical response, not arbitrary duration
Prevention and recurrence reduction
Treat tinea pedis aggressively
Topical antifungals remove primary portal of entry
Oral antifungals for recalcitrant tinea
Compression therapy for lymphedema
Reduces bacterial burden in edematous tissue
Improves lymphatic flow and immunity
Antibiotic prophylaxis for recurrent cases
Penicillin V 250 mg PO twice daily continuous prophylaxis
Erythromycin 250 mg PO twice daily if penicillin allergic
Reduces recurrence rate by approximately 50% (Class IIa recommendation)
Patient Discharge Instructions
copy discharge instructions
Lymphangitis home care
Take all antibiotics exactly as prescribed until finished
Do not stop early even if feeling better
Duration is typically 5 to 7 days or as specified
Elevate the affected limb
Rest with arm or leg raised above heart level
Reduces swelling and pain
Rest and adequate fluids
Avoid strenuous activity until streaking resolves
Maintain good oral fluid intake
Mark the red streak with a pen at the edges
Check every few hours for advancing redness beyond the mark
A line that advances past the mark is an emergency
Warning signs to return to the ER immediately
Red streak advancing past the marked border
Means antibiotics may not be working
Do not wait for next-day appointment
High fever (above 39 C or 102 F) or fever returning after it resolved
May indicate spreading infection or bacteremia
New confusion, severe dizziness, or near-fainting
Signs of sepsis requiring urgent assessment
Skin turning dark, purple, or black
May indicate a serious deep infection (necrotizing fasciitis)
Surgical emergency
Inability to keep antibiotics down due to vomiting
IV antibiotics may be needed
Swelling and redness spreading to the chest, belly, or groin
Indicates proximal lymphatic spread
Follow-up instructions
Reassessment by a clinician in 24 to 48 hours
Earlier if any warning signs develop
Photograph the affected area daily for comparison
If this is a recurring problem, ask about a lymphedema specialist referral
Compression garments and physiotherapy may reduce future episodes
Treat any fungal foot infection (athlete's foot) with antifungal cream
This is the most common entry point for leg infections
Keep feet clean and dry to prevent recurrence
References
Guidelines and key sources
IDSA guidelines
IDSA Practice Guidelines for Skin and Soft Tissue Infections (Stevens et al, 2014 and 2023 update)
5-day minimum antibiotic duration for non-purulent SSTI
IV therapy for >= 2 SIRS criteria
IDSA recommendation against routine wound cultures in non-purulent lymphangitis
Low yield from superficial swabs
Class I recommendation
Evidence summaries
Eron classification system for SSTI severity
Published in Lancet Infectious Diseases 2003
Guides outpatient versus inpatient decision
Nodular lymphangitis review (Freedman et al)
Differential for sporotrichoid pattern including Sporothrix, M. marinum, Nocardia, Leishmania, Francisella
Tissue biopsy and culture required for definitive diagnosis
Lymphedema and recurrent SSTI
OR 6.8 for recurrent cellulitis in lymphedema (Moffatt et al, BMJ)
Prophylactic penicillin reduces recurrence by approximately 50% (Thomas et al, NEJM)
Coding standards
ICD-10 I89.1 Lymphangitis
ICD-10 L03.90 Cellulitis unspecified
ICD-10 M72.6 Necrotizing fasciitis (must be excluded)
SNOMED CT lymphangitis disorder concept
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.